Summary
Global Markets Direct’s, ‘Gastric Cancer - Pipeline Review, H1 2016’, provides an overview of the Gastric Cancer pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Gastric Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Gastric Cancer
- The report reviews pipeline therapeutics for Gastric Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Gastric Cancer therapeutics and enlists all their major and minor projects
- The report assesses Gastric Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Gastric Cancer
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Gastric Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Gastric Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AB Science SA
AbbVie Inc.
AbGenomics International, Inc.
ADC Therapeutics Sarl
Advaxis, Inc.
Advenchen Laboratories, LLC
Agenus, Inc.
Ambrx, Inc.
Amgen Inc.
arGEN-X BV
Aslan Pharmaceuticals Pte. Ltd.
Astellas Pharma Inc.
AstraZeneca Plc
Atara Biotherapeutics, Inc.
Athenex, Inc.
Azaya Therapeutics, Inc.
Basilea Pharmaceutica AG
Bayer AG
BeiGene, Ltd.
Betta Pharmaceuticals Co. Ltd.
Bionovis SA
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Celgene Corporation
Celldex Therapeutics, Inc.
Cellectar Biosciences, Inc.
Celltrion, Inc.
Celon Pharma Sp. z o.o.
Cerulean Pharma, Inc.
Chipscreen Biosciences Ltd
Chugai Pharmaceutical Co., Ltd.
Compliment Corporation
Curaxys, S.L.
DAE HWA Pharmaceutical Co., Ltd.
Daiichi Sankyo Company, Limited
Deciphera Pharmaceuticals, LLC
Dr. Reddy's Laboratories Limited
Eddingpharm
EirGenix Inc.
Eli Lilly and Company
Esperance Pharmaceuticals, Inc.
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
Frost Biologic, Inc.
Galena Biopharma, Inc.
Genelux Corporation
Genentech, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
GlycoNex Inc.
Glycotope GmbH
Green Cross Corporation
Halozyme Therapeutics, Inc.
Hanmi Pharmaceuticals, Co. Ltd.
Hetero Drugs Limited
Horizon Pharma Plc
Hutchison MediPharma Limited
Ignyta, Inc.
Immunomedics, Inc.
Incyte Corporation
Innovent Biologics, Inc.
INSYS Therapeutics, Inc.
ISU ABXIS Co.,Ltd.
Jiangsu Hengrui Medicine Co., Ltd.
Jiangsu Kanion Pharmaceutical Co., Ltd.
Johnson & Johnson
KaloBios Pharmaceuticals, Inc.
Karyopharm Therapeutics, Inc.
Kolltan Pharmaceuticals, Inc.
Kuhnil Pharmaceutical Co., Ltd.
Kyowa Hakko Kirin Co., Ltd.
LegoChem Biosciences, Inc
Les Laboratoires Servier SAS
MacroGenics, Inc.
Mebiopharm Co., Ltd.
MedImmune, LLC
Medivation, Inc.
Merck & Co., Inc.
Merck KGaA
Merrimack Pharmaceuticals, Inc.
Mersana Therapeutics, Inc.
Merus B.V.
Millennium Pharmaceuticals, Inc.
Molecular Targeting Technologies, Inc.
MolMed S.p.A.
NanoCarrier Co., Ltd.
Novartis AG
OBI Pharma, Inc.
Omnitura Therapeutics Inc.
Oncobiologics, Inc.
Oncolys BioPharma Inc.
Oncolytics Biotech Inc.
OncoTherapy Science, Inc.
Ono Pharmaceutical Co., Ltd.
Panacea Biotec Limited
Patrys Limited
Pfizer Inc.
Pharma Mar, S.A.
Pharmacyclics, Inc.
Puma Biotechnology, Inc.
Rexahn Pharmaceuticals, Inc.
Richter Gedeon Nyrt.
Sanofi
Sareum Holdings Plc
Sequella, Inc.
Shanghai Henlius Biotech Co., Ltd.
Shionogi & Co., Ltd.
Sihuan Pharmaceutical Holdings Group Ltd.
Simcere Pharmaceutical Group
Sorrento Therapeutics, Inc.
Spectrum Pharmaceuticals, Inc.
Sunesis Pharmaceuticals, Inc.
Supratek Pharma Inc.
Synovo GmbH
Synta Pharmaceuticals Corp.
Synthon Holdings BV
Taiho Pharmaceutical Co., Ltd.
Takeda Pharmaceutical Company Limited
Takis S.r.l.
Tara Immuno-Oncology Therapeutics LLC
TG Therapeutics, Inc.
Transgene SA
Vaxon Biotech
ViiV Healthcare Limited
Zymeworks Inc.
'
Table of Contents
Table of Contents 2
Introduction 8
Gastric Cancer Overview 9
Therapeutics Development 10
Gastric Cancer - Therapeutics under Development by Companies 12
Gastric Cancer - Therapeutics under Investigation by Universities/Institutes 23
Gastric Cancer - Pipeline Products Glance 24
Gastric Cancer - Products under Development by Companies 28
Gastric Cancer - Products under Investigation by Universities/Institutes 44
Gastric Cancer - Companies Involved in Therapeutics Development 45
Gastric Cancer - Therapeutics Assessment 172
Drug Profiles 193
Gastric Cancer - Recent Pipeline Updates 617
Gastric Cancer - Dormant Projects 914
Gastric Cancer - Discontinued Products 925
Gastric Cancer - Product Development Milestones 928
Appendix 936
List of Tables
Number of Products under Development for Gastric Cancer, H1 2016 35
Number of Products under Development for Gastric Cancer - Comparative Analysis, H1 2016 36
Number of Products under Development by Companies, H1 2016 37
Number of Products under Development by Companies, H1 2016 (Contd..1) 38
Number of Products under Development by Companies, H1 2016 (Contd..2) 39
Number of Products under Development by Companies, H1 2016 (Contd..3) 40
Number of Products under Development by Companies, H1 2016 (Contd..4) 41
Number of Products under Development by Companies, H1 2016 (Contd..5) 42
Number of Products under Development by Companies, H1 2016 (Contd..6) 43
Number of Products under Development by Companies, H1 2016 (Contd..7) 44
Number of Products under Development by Companies, H1 2016 (Contd..8) 45
Number of Products under Development by Companies, H1 2016 (Contd..9) 46
Number of Products under Development by Companies, H1 2016 (Contd..10) 47
Number of Products under Investigation by Universities/Institutes, H1 2016 48
Comparative Analysis by Late Stage Development, H1 2016 49
Comparative Analysis by Clinical Stage Development, H1 2016 50
Comparative Analysis by Early Stage Development, H1 2016 51
Comparative Analysis by Unknown Stage Development, H1 2016 52
Products under Development by Companies, H1 2016 53
Products under Development by Companies, H1 2016 (Contd..1) 54
Products under Development by Companies, H1 2016 (Contd..2) 55
Products under Development by Companies, H1 2016 (Contd..3) 56
Products under Development by Companies, H1 2016 (Contd..4) 57
Products under Development by Companies, H1 2016 (Contd..5) 58
Products under Development by Companies, H1 2016 (Contd..6) 59
Products under Development by Companies, H1 2016 (Contd..7) 60
Products under Development by Companies, H1 2016 (Contd..8) 61
Products under Development by Companies, H1 2016 (Contd..9) 62
Products under Development by Companies, H1 2016 (Contd..10) 63
Products under Development by Companies, H1 2016 (Contd..11) 64
Products under Development by Companies, H1 2016 (Contd..12) 65
Products under Development by Companies, H1 2016 (Contd..13) 66
Products under Development by Companies, H1 2016 (Contd..14) 67
Products under Development by Companies, H1 2016 (Contd..15) 68
Products under Investigation by Universities/Institutes, H1 2016 69
Gastric Cancer - Pipeline by AB Science SA, H1 2016 70
Gastric Cancer - Pipeline by AbbVie Inc., H1 2016 71
Gastric Cancer - Pipeline by AbGenomics International, Inc., H1 2016 72
Gastric Cancer - Pipeline by ADC Therapeutics Sarl, H1 2016 73
Gastric Cancer - Pipeline by Advaxis, Inc., H1 2016 74
Gastric Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016 75
Gastric Cancer - Pipeline by Agenus, Inc., H1 2016 76
Gastric Cancer - Pipeline by Ambrx, Inc., H1 2016 77
Gastric Cancer - Pipeline by Amgen Inc., H1 2016 78
Gastric Cancer - Pipeline by arGEN-X BV, H1 2016 79
Gastric Cancer - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2016 80
Gastric Cancer - Pipeline by Astellas Pharma Inc., H1 2016 81
Gastric Cancer - Pipeline by AstraZeneca Plc, H1 2016 82
Gastric Cancer - Pipeline by Atara Biotherapeutics, Inc., H1 2016 83
Gastric Cancer - Pipeline by Athenex, Inc., H1 2016 84
Gastric Cancer - Pipeline by Azaya Therapeutics, Inc., H1 2016 85
Gastric Cancer - Pipeline by Basilea Pharmaceutica AG, H1 2016 86
Gastric Cancer - Pipeline by Bayer AG, H1 2016 87
Gastric Cancer - Pipeline by BeiGene, Ltd., H1 2016 88
Gastric Cancer - Pipeline by Betta Pharmaceuticals Co. Ltd., H1 2016 89
Gastric Cancer - Pipeline by Bionovis SA, H1 2016 90
Gastric Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016 91
Gastric Cancer - Pipeline by Boston Biomedical, Inc., H1 2016 92
Gastric Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016 93
Gastric Cancer - Pipeline by Celgene Corporation, H1 2016 94
Gastric Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2016 95
Gastric Cancer - Pipeline by Cellectar Biosciences, Inc., H1 2016 96
Gastric Cancer - Pipeline by Celltrion, Inc., H1 2016 97
Gastric Cancer - Pipeline by Celon Pharma Sp. z o.o., H1 2016 98
Gastric Cancer - Pipeline by Cerulean Pharma, Inc., H1 2016 99
Gastric Cancer - Pipeline by Chipscreen Biosciences Ltd, H1 2016 100
Gastric Cancer - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2016 101
Gastric Cancer - Pipeline by Compliment Corporation, H1 2016 102
Gastric Cancer - Pipeline by Curaxys, S.L., H1 2016 103
Gastric Cancer - Pipeline by DAE HWA Pharmaceutical Co., Ltd., H1 2016 104
Gastric Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 105
Gastric Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2016 106
Gastric Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016 107
Gastric Cancer - Pipeline by Eddingpharm, H1 2016 108
Gastric Cancer - Pipeline by EirGenix Inc., H1 2016 109
Gastric Cancer - Pipeline by Eli Lilly and Company, H1 2016 110
Gastric Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H1 2016 111
Gastric Cancer - Pipeline by Exelixis, Inc., H1 2016 112
Gastric Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 113
Gastric Cancer - Pipeline by Five Prime Therapeutics, Inc., H1 2016 114
Gastric Cancer - Pipeline by Frost Biologic, Inc., H1 2016 115
Gastric Cancer - Pipeline by Galena Biopharma, Inc., H1 2016 116
Gastric Cancer - Pipeline by Genelux Corporation, H1 2016 117
Gastric Cancer - Pipeline by Genentech, Inc., H1 2016 118
Gastric Cancer - Pipeline by Gilead Sciences, Inc., H1 2016 119
Gastric Cancer - Pipeline by GlaxoSmithKline Plc, H1 2016 120
Gastric Cancer - Pipeline by GlycoNex Inc., H1 2016 121
Gastric Cancer - Pipeline by Glycotope GmbH, H1 2016 122
Gastric Cancer - Pipeline by Green Cross Corporation, H1 2016 123
Gastric Cancer - Pipeline by Halozyme Therapeutics, Inc., H1 2016 124
Gastric Cancer - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 125
Gastric Cancer - Pipeline by Hetero Drugs Limited, H1 2016 126
Gastric Cancer - Pipeline by Horizon Pharma Plc, H1 2016 127
Gastric Cancer - Pipeline by Hutchison MediPharma Limited, H1 2016 128
Gastric Cancer - Pipeline by Ignyta, Inc., H1 2016 129
Gastric Cancer - Pipeline by Immunomedics, Inc., H1 2016 130
Gastric Cancer - Pipeline by Incyte Corporation, H1 2016 131
Gastric Cancer - Pipeline by Innovent Biologics, Inc., H1 2016 132
Gastric Cancer - Pipeline by INSYS Therapeutics, Inc., H1 2016 133
Gastric Cancer - Pipeline by ISU ABXIS Co.,Ltd., H1 2016 134
Gastric Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016 135
Gastric Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2016 136
Gastric Cancer - Pipeline by Johnson & Johnson, H1 2016 137
Gastric Cancer - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2016 138
Gastric Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 139
Gastric Cancer - Pipeline by Kolltan Pharmaceuticals, Inc., H1 2016 140
Gastric Cancer - Pipeline by Kuhnil Pharmaceutical Co., Ltd., H1 2016 141
Gastric Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 142
Gastric Cancer - Pipeline by LegoChem Biosciences, Inc, H1 2016 143
Gastric Cancer - Pipeline by Les Laboratoires Servier SAS, H1 2016 144
Gastric Cancer - Pipeline by MacroGenics, Inc., H1 2016 145
Gastric Cancer - Pipeline by Mebiopharm Co., Ltd., H1 2016 146
Gastric Cancer - Pipeline by MedImmune, LLC, H1 2016 147
Gastric Cancer - Pipeline by Medivation, Inc., H1 2016 148
Gastric Cancer - Pipeline by Merck & Co., Inc., H1 2016 149
Gastric Cancer - Pipeline by Merck KGaA, H1 2016 150
Gastric Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016 151
Gastric Cancer - Pipeline by Mersana Therapeutics, Inc., H1 2016 152
Gastric Cancer - Pipeline by Merus B.V., H1 2016 153
Gastric Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 154
Gastric Cancer - Pipeline by Molecular Targeting Technologies, Inc., H1 2016 155
Gastric Cancer - Pipeline by MolMed S.p.A., H1 2016 156
Gastric Cancer - Pipeline by NanoCarrier Co., Ltd., H1 2016 157
Gastric Cancer - Pipeline by Novartis AG, H1 2016 158
Gastric Cancer - Pipeline by OBI Pharma, Inc., H1 2016 159
Gastric Cancer - Pipeline by Omnitura Therapeutics Inc., H1 2016 160
Gastric Cancer - Pipeline by Oncobiologics, Inc., H1 2016 161
Gastric Cancer - Pipeline by Oncolys BioPharma Inc., H1 2016 162
Gastric Cancer - Pipeline by Oncolytics Biotech Inc., H1 2016 163
Gastric Cancer - Pipeline by OncoTherapy Science, Inc., H1 2016 164
Gastric Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 165
Gastric Cancer - Pipeline by Panacea Biotec Limited, H1 2016 166
Gastric Cancer - Pipeline by Patrys Limited, H1 2016 167
Gastric Cancer - Pipeline by Pfizer Inc., H1 2016 168
Gastric Cancer - Pipeline by Pharma Mar, S.A., H1 2016 169
Gastric Cancer - Pipeline by Pharmacyclics, Inc., H1 2016 170
Gastric Cancer - Pipeline by Puma Biotechnology, Inc., H1 2016 171
Gastric Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2016 172
Gastric Cancer - Pipeline by Richter Gedeon Nyrt., H1 2016 173
Gastric Cancer - Pipeline by Sanofi, H1 2016 174
Gastric Cancer - Pipeline by Sareum Holdings Plc, H1 2016 175
Gastric Cancer - Pipeline by Sequella, Inc., H1 2016 176
Gastric Cancer - Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2016 177
Gastric Cancer - Pipeline by Shionogi & Co., Ltd., H1 2016 178
Gastric Cancer - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016 179
Gastric Cancer - Pipeline by Simcere Pharmaceutical Group, H1 2016 180
Gastric Cancer - Pipeline by Sorrento Therapeutics, Inc., H1 2016 181
Gastric Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016 182
Gastric Cancer - Pipeline by Sunesis Pharmaceuticals, Inc., H1 2016 183
Gastric Cancer - Pipeline by Supratek Pharma Inc., H1 2016 184
Gastric Cancer - Pipeline by Synovo GmbH, H1 2016 185
Gastric Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2016 186
Gastric Cancer - Pipeline by Synthon Holdings BV, H1 2016 187
Gastric Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016 188
Gastric Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 189
Gastric Cancer - Pipeline by Takis S.r.l., H1 2016 190
Gastric Cancer - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H1 2016 191
Gastric Cancer - Pipeline by TG Therapeutics, Inc., H1 2016 192
Gastric Cancer - Pipeline by Transgene SA, H1 2016 193
Gastric Cancer - Pipeline by Vaxon Biotech, H1 2016 194
Gastric Cancer - Pipeline by ViiV Healthcare Limited, H1 2016 195
Gastric Cancer - Pipeline by Zymeworks Inc., H1 2016 196
Assessment by Monotherapy Products, H1 2016 197
Assessment by Combination Products, H1 2016 198
Number of Products by Stage and Target, H1 2016 200
Number of Products by Stage and Mechanism of Action, H1 2016 208
Number of Products by Stage and Route of Administration, H1 2016 215
Number of Products by Stage and Molecule Type, H1 2016 217
Gastric Cancer Therapeutics - Recent Pipeline Updates, H1 2016 642
Gastric Cancer - Dormant Projects, H1 2016 939
Gastric Cancer - Dormant Projects (Contd..1), H1 2016 940
Gastric Cancer - Dormant Projects (Contd..2), H1 2016 941
Gastric Cancer - Dormant Projects (Contd..3), H1 2016 942
Gastric Cancer - Dormant Projects (Contd..4), H1 2016 943
Gastric Cancer - Dormant Projects (Contd..5), H1 2016 944
Gastric Cancer - Dormant Projects (Contd..6), H1 2016 945
Gastric Cancer - Dormant Projects (Contd..7), H1 2016 946
Gastric Cancer - Dormant Projects (Contd..8), H1 2016 947
Gastric Cancer - Dormant Projects (Contd..9), H1 2016 948
Gastric Cancer - Dormant Projects (Contd..10), H1 2016 949
Gastric Cancer - Discontinued Products, H1 2016 950
Gastric Cancer - Discontinued Products (Contd..1), H1 2016 951
Gastric Cancer - Discontinued Products (Contd..2), H1 2016 952
List of Figures
Number of Products under Development for Gastric Cancer, H1 2016 35
Number of Products under Development for Gastric Cancer - Comparative Analysis, H1 2016 36
Number of Products under Development by Companies, H1 2016 37
Number of Products under Investigation by Universities/Institutes, H1 2016 48
Comparative Analysis by Clinical Stage Development, H1 2016 50
Comparative Analysis by Early Stage Products, H1 2016 51
Assessment by Monotherapy Products, H1 2016 197
Assessment by Combination Products, H1 2016 198
Number of Products by Top 10 Targets, H1 2016 199
Number of Products by Stage and Top 10 Targets, H1 2016 199
Number of Products by Top 10 Mechanism of Actions, H1 2016 207
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 207
Number of Products by Top 10 Routes of Administration, H1 2016 214
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 214
Number of Products by Top 10 Molecule Types, H1 2016 216
Number of Products by Stage and Top 10 Molecule Types, H1 2016 216
